TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9322120

Group type: EXPERIMENTAL
Intervention: Previous gastric resection in patients dying from pancreatic carcinoma; prevalence 3.4%.
Number of subjects: 439

Group type: COMPARATOR
Intervention: Previous gastric resection in patients dying from lung cancer; prevalence 7.6%.
Number of subjects: 439

Group type: COMPARATOR
Intervention: Age- and sex-matched control group; prevalence 4.4%.
Number of subjects: 439
Study: 8400608

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (500 mg/day calcium intake)
Number of subjects: 44
Study: 31493549

Group type: EXPERIMENTAL
Intervention: Real-tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 12
Study: 29664663

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study: 27055019

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 106

Group type: COMPARATOR
Intervention: BCG vaccination at 14 weeks of age
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: HEU infants
Number of subjects: 106
Study: 24812434

Group type: EXPERIMENTAL
Intervention: Intensive glucose treatment group
Number of subjects: 4399
Study: 22921287

Group type: EXPERIMENTAL
Intervention: Mirodenafil 100 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19651694

Group type: EXPERIMENTAL
Intervention: Structured educational programme
Number of subjects: 82

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 82
Study: 18628517

Group type: EXPERIMENTAL
Intervention: LBW subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 20
Study: 16858939

Group type: EXPERIMENTAL
Intervention: BVBLUE test
Number of subjects: 173

Group type: COMPARATOR
Intervention: Gram stain (Nugent score as gold standard)
Number of subjects: 173
Study: 11924872

Group type: EXPERIMENTAL
Intervention: Exposure to a connected mobile phone (900 MHz) for 30 min
Number of subjects: 38

Group type: COMPARATOR
Intervention: Mobile phone switched off (control group)
Number of subjects: 38
Study: 10715366

Group type: EXPERIMENTAL
Intervention: Alesse (20 micrograms ethinyl estradiol)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Mircette (20 micrograms ethinyl estradiol)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Ortho Tri‐Cyclen (35 micrograms ethinyl estradiol)
Number of subjects: 463

Group type: COMPARATOR
Intervention: 35 micrograms ethinyl estradiol
Number of subjects: 463
Study: 7854172

Group type: EXPERIMENTAL
Intervention: Nicotine gum use after quitting smoking
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: No nicotine exposure after quitting smoking
Number of subjects: 221

Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Change in smoking status
Number of subjects: 221
Study: 2015151

Group type: EXPERIMENTAL
Intervention: Trimetaphan 0.05 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trimetaphan 0.1 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study: 6461678

Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy (13‐cis‐retinoic acid) discontinued for at least 20 weeks
Number of subjects: 20
Study: 30834647

Group type: EXPERIMENTAL
Intervention: Comprehensive medication reviews (CMRs) by ward-based pharmacists including follow-up telephone calls after hospital discharge.
Number of subjects: 15
Study: 30769063

Group type: EXPERIMENTAL
Intervention: Heparin-bonded PTFE graft
Number of subjects: 228

Group type: COMPARATOR
Intervention: Crude PTFE graft
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 228
Study: 26721873

Group type: EXPERIMENTAL
Intervention: Wii.n.Walk (Wii Fit training, 3x/week for 40 minutes over 4 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cognitive games (Control group)
Number of subjects: 28
Study: 26018207

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 25
Study: 22538473

Group type: EXPERIMENTAL
Intervention: Particulated autogenous bone (PAB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mixtures of PAB and beta‐tricalciumphosphate (PAB/β‐TCP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mixtures of PAB and β‐TCP and hydroxyapatite (PAB/HA/β‐TCP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (PAB alone)
Number of subjects: 30
Study: 21389859

Group type: EXPERIMENTAL
Intervention: Emergency medicine rotation (theoretical and practical course)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Pretest scores
Number of subjects: 98
Study: 19321990

Group type: EXPERIMENTAL
Intervention: SnF(2) (approx. 0.1 M F)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: HF (0.027, 0.055, 0.082 M F)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: TiF(4)
Number of subjects: 67

Group type: COMPARATOR
Intervention: NaF (0.1 M F)
Number of subjects: 67
Study: 17367306

Group type: EXPERIMENTAL
Intervention: Empowerment education programme
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Empowerment education programme with parental involvement
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (wait-list design)
Number of subjects: 32
Study: 15362205

Group type: EXPERIMENTAL
Intervention: MMP9 expression
Number of subjects: 41
Study: 11848262

Group type: EXPERIMENTAL
Intervention: 2 mg perindopril and 0.625 mg indapamide
Number of subjects: 235

Group type: COMPARATOR
Intervention: 2 mg perindopril
Number of subjects: 235

Group type: COMPARATOR
Intervention: 0.625 mg indapamide
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235

Group type: COMPARATOR
Intervention: Combination vs Losartan
Number of subjects: 235
Study: 10437260

Group type: EXPERIMENTAL
Intervention: Filiform needle group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Point-injection group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Western medicine group
Number of subjects: 48
Study: 7873261

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mgs/12 h i.v.)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Cimetidine (1,200 mgs/i.v./day)
Number of subjects: 282
Study: 3279578

Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 55

Group type: COMPARATOR
Intervention: Azathioprine + low-dose steroids
Number of subjects: 55

Group type: COMPARATOR
Intervention: High-dose steroids
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low-dose steroids
Number of subjects: 55
Study: 30755451

Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship (AMS) intervention
Number of subjects: 79

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: AMS intervention
Number of subjects: 79
Study: 29221470

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 60
Study: 26011593

Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control (ongoing guideline-directed medical and device therapy)
Number of subjects: 146
Study: 24800384

Group type: EXPERIMENTAL
Intervention: Dietary fibre intake
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fluid intake
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Physical activity levels
Number of subjects: 90
Study: 21616115

Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 200000

Group type: COMPARATOR
Intervention: Control group (no BCG revaccination)
Number of subjects: 200000
Study: 19671875

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cyclophosphamide, i.v. methotrexate, and 5-fluorouracil or cyclophosphamide, i.v. doxorubicin, and 5-fluorouracil +/- tamoxifen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 0
Study: 17116185

Group type: EXPERIMENTAL
Intervention: 10 microg lipo‐PGE(1) given as a continuous infusion over 5 days, along with 48 mg methylprednisolone for 5 days
Number of subjects: 270

Group type: COMPARATOR
Intervention: Saline (placebo) along with 48 mg methylprednisolone for 5 days
Number of subjects: 270
Study: 15209960

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ketotifen
Number of subjects: 26
Study: 11727357

Group type: EXPERIMENTAL
Intervention: E2 + TMG (2 mg estradiol and 0.5 mg trimegestone)
Number of subjects: 634

Group type: COMPARATOR
Intervention: E2V + NG (estradiol valerate and norgestrel)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: E2 + TMG
Number of subjects: 634

Group type: COMPARATOR
Intervention: E2V + NG
Number of subjects: 634
Study: 9135704

Group type: EXPERIMENTAL
Intervention: 2.5 mg oxandrolone daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 mg testosterone monthly intramuscular injections
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7963510

Group type: EXPERIMENTAL
Intervention: High sodium intake (350 mmol/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low sodium intake (10 mmol/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal sodium intake (control)
Number of subjects: 12
Study: 3070420

Group type: EXPERIMENTAL
Intervention: Intravenous Nimodipine
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 188
Study: 30601058

Group type: EXPERIMENTAL
Intervention: Subacromial decompression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arthroscopy only (placebo surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 28546319

Group type: EXPERIMENTAL
Intervention: IPS‐MA
Number of subjects: 326

Group type: COMPARATOR
Intervention: SAU
Number of subjects: 326
Study: 26906448

Group type: EXPERIMENTAL
Intervention: Out-and-About program (behavior change program with training workshop, barrier identification, booster session, printed educational materials, audit, and feedback)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Out-and-About program (behavior change program)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (printed clinical guidelines only)
Number of subjects: 22
Study: 25011691

Group type: EXPERIMENTAL
Intervention: Manic patients
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 110

Group type: COMPARATOR
Intervention: Euthymic patients
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mixed patients
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Duration of illness
Number of subjects: 110
Study: 23075000

Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention with individualized email-based feedback for 10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: General supportive/motivational messages (for both INT and CTL)
Number of subjects: 0
Study: 18753471

Group type: COMPARATOR
Intervention: 1.5 mg of morphine plus saline solution (MO)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1.0 mg of morphine plus a 5-mg ketamine bolus (MK)
Number of subjects: 41
Study: 17242418

Group type: EXPERIMENTAL
Intervention: Combined treatments (psychosocial and pharmacological)
Number of subjects: 8
Study: 14684584

Group type: EXPERIMENTAL
Intervention: VSL#3 6 g once daily for one year
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo once daily for one year
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12116511

Group type: EXPERIMENTAL
Intervention: Whitening strips containing hydrogen peroxide
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Discontinuance of the whitening agent
Number of subjects: 132
Study: 10836083

Group type: EXPERIMENTAL
Intervention: Carlens tube
Number of subjects: 62

Group type: COMPARATOR
Intervention: Robertshaw tube
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Robertshaw tube with fiberoptic bronchoscope
Number of subjects: 62
Study: 8583095

Group type: EXPERIMENTAL
Intervention: Heater probe thermocoagulation (HPT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Multipolar electrocoagulation (MPEC)
Number of subjects: 80
Study: 2252171

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with methohexital and fentanyl
Number of subjects: 18

Group type: COMPARATOR
Intervention: Combined anaesthesia with alfentanil and N2O
Number of subjects: 18
Study: 31259

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nonselective beta-blockers
Number of subjects: 27
Study: 31268223

Group type: EXPERIMENTAL
Intervention: GroupCoreDIST
Number of subjects: 80
Study: 31282768

Group type: EXPERIMENTAL
Intervention: TX‐001HR (1/100 mg, 0.5/100 mg, 0.5/50 mg, 0.25/50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TX‐001HR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TX‐001HR (1 mg/100 mg)
Number of subjects: 0
Study: 27680426

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ankle-Foot Orthosis (AFO)
Number of subjects: 20
Study: 26080370

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 198
Study: 23627534

Group type: EXPERIMENTAL
Intervention: Enriched Environment (EE)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-enriched environment (Control)
Number of subjects: 29
Study: 22324056

Group type: EXPERIMENTAL
Intervention: Compensation group treatment programme
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Restitution group treatment programme
Number of subjects: 72

Group type: COMPARATOR
Intervention: Self-help group control
Number of subjects: 72
Study: 19438472

Group type: EXPERIMENTAL
Intervention: G-CSF (Lenograstim, 263 microg/d)
Number of subjects: 803

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study: 17263856

Group type: EXPERIMENTAL
Intervention: Xylitol-containing chewing gum (total dose=6.18 g/day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Sorbitol and maltitol-containing pellets
Number of subjects: 128
Study: 16281887

Group type: EXPERIMENTAL
Intervention: Volunteers
Number of subjects: 12866

Group type: COMPARATOR
Intervention: Men excluded for presence of disease
Number of subjects: 12866

Group type: COMPARATOR
Intervention: Men excluded with characteristics likely to interfere with adherence
Number of subjects: 12866
Study: 11427330

Group type: EXPERIMENTAL
Intervention: Oral rizatriptan 5 mg
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 50 mg
Number of subjects: 792

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Categorical Four-Grade Scale (4GS)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Rizatriptan and Sumatriptan
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: VAS and 4GS scores
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: VAS
Number of subjects: 792
Study: 9727571

Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 1090
Study: 11271338

Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 540

Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 540
Study: 2140663

Group type: EXPERIMENTAL
Intervention: Combination of 2 mg cyproterone acetate (CPA) with 0.035 mg ethinyl estradiol (EE) (Diane 35)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Combination of 0.150 mg desogestrel (DG) with 0.03 mg ethinyl estradiol (EE) (Marvelon)
Number of subjects: 162
Study: 301797

Group type: EXPERIMENTAL
Intervention: Internal Mammary Artery Graft (IMAG)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Saphenous Vein Bypass Graft (SVBG)
Number of subjects: 74
Study: 31187238

Group type: EXPERIMENTAL
Intervention: Supervised intensive vestibular rehabilitation with visual biofeedback (postoperative rehabilitation program)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Prehabilitation with intratympanic application of gentamicin
Number of subjects: 52
Study: 27402501

Group type: EXPERIMENTAL
Intervention: Anesthetist-directed sedation (ADS)
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Gastroenterologist-directed sedation (GDS)
Number of subjects: 1171
Study: 25938614

Group type: EXPERIMENTAL
Intervention: 3-month intensive meditation retreat
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 60
Study: 24100786

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 21757515

Group type: EXPERIMENTAL
Intervention: 3T MR imaging (PD sequence)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3T MR imaging (GM sequence)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Correlation of LGN height and volume with clinical glaucoma stage
Number of subjects: 26
Study: 19368512

Group type: EXPERIMENTAL
Intervention: Topical vitamin B(12)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 17516069

Group type: EXPERIMENTAL
Intervention: Milataxel (35 mg/m², administered intravenously every 3 weeks)
Number of subjects: 44
Study: 15477049

Group type: COMPARATOR
Intervention: Intrathecal 0.5% bupivacaine 7.5 mg with saline 1 mL (group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% bupivacaine 7.5 mg with fentanyl 10 microg (group Bf10)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% bupivacaine 7.5 mg with fentanyl 20 microg (group Bf20)
Number of subjects: 45
Study: 11926203

Group type: EXPERIMENTAL
Intervention: 1 g of ascorbic acid (AA) daily for four weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9716147

Group type: EXPERIMENTAL
Intervention: aPCR-tissue factor-based assay
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: aPCR-dRVVT-based assay
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both assays (when negative)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Polymerase chain reaction analysis
Number of subjects: 82
Study: 7989900

Group type: EXPERIMENTAL
Intervention: Comprehensive multiple risk factor modification programme
Number of subjects: 508

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 508
Study: 4916211

Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 1-hyoscyamine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Inert tablets (placebo)
Number of subjects: 106
Study: 1233216

Group type: EXPERIMENTAL
Intervention: Propranolol (0.06 mg/kg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol (0.12 mg/kg i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoprenaline (increasing doses)
Number of subjects: 0
Study: 31486684

Group type: EXPERIMENTAL
Intervention: Combination therapy with Deferoxamine (DFO) and Deferasirox (DFX)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Deferoxamine (DFO)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Deferiprone (DFP)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Deferasirox (DFX)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Combination therapy (not specified)
Number of subjects: 256
Study: 28303670

Group type: EXPERIMENTAL
Intervention: Z-stitch
Number of subjects: 86

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 86
Study: 26195078

Group type: EXPERIMENTAL
Intervention: SSV as LIV (n = 20)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: FLV as LIV (n = 16)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SSV and FLV as the same vertebra (n = 18)
Number of subjects: 54

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 54
Study: 25205516

Group type: EXPERIMENTAL
Intervention: Neighborhood with moderate median household income (between $36,147 and $53,099)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Neighborhood with low median household income (<$36,147)
Number of subjects: 801
Study: 22713632

Group type: EXPERIMENTAL
Intervention: Alfentanil (μ‐opioid receptor agonist)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 242
Study: 21137282

Group type: EXPERIMENTAL
Intervention: Open vertebroplasty combined with short-segmental pedicle screw fixation
Number of subjects: 21
Study: 18068589

Group type: EXPERIMENTAL
Intervention: Hawley retainers
Number of subjects: 397

Group type: COMPARATOR
Intervention: Vacuum-formed retainers (VFRs)
Number of subjects: 397
Study: 15890794

Group type: EXPERIMENTAL
Intervention: Graded doses of a selective gonadotropin releasing hormone (GnRH)‐receptor antagonist
Number of subjects: 18
Study: 12523577

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) 7.5 to 15 mg/kg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (non-ATG)
Number of subjects: 160
Study: 9713561

Group type: EXPERIMENTAL
Intervention: Induced hypocalcaemia (blood ionized calcium lowered by 0.20 mmol/l within 30 min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Induced hypocalcaemia followed by a brief return to normocalcaemia (protocol 1)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Induced hypocalcaemia from the initial hypocalcaemic level of blood ionized calcium (protocol 2)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Induced hypercalcaemia followed by hypocalcaemia (protocol 3)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Initial induction of hypocalcaemia and first recovery from hypocalcaemia (protocol 3)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Second recovery from induced hypocalcaemia (protocol 3)
Number of subjects: 11
Study: 8129213

Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate 0.5 to 3.5 mg by continuous-flow nebulization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 2563320

Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of Terfenadine and Flurbiprofen
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 4469040

Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Desipramine (added to indoramin)
Number of subjects: 15